New diabetes clinical trial: IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion

Published on: January 22, 2026 at 11:00PM
Conditions: Mild Autonomous Cortisol Secretion (MACS); Autonomous Cortisol Secretion (ACS); Subclinical Cushing's; Mild Autonomous Cortisol Excess
Interventions: Procedure: Intervention 1: Adrenalectomy; Drug: Intervention 2: Semaglutide
Sponsors: University of Texas Southwestern Medical Center; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not yet recruiting
https://ift.tt/HOnRuUi